Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Enzinger

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
The Oncologist|January 21, 2025
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsKimberly Perez, Matthew H Kulke, Hui Zheng, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
The Oncologist|February 23, 2013
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerMichael S Lee, Harvey J Mamon, Theodore S Hong, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.
BMC Cancer|July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancerJames M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
The Oncologist|January 21, 2025
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsKimberly Perez, Matthew H Kulke, Hui Zheng, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
The Oncologist|February 23, 2013
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerMichael S Lee, Harvey J Mamon, Theodore S Hong, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.
BMC Cancer|July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancerJames M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Pageof 10